We Computerize Drug Discovery

“A Talent for following the ways of yesterday is not sufficient to improve the world of today.”

King Wu-ling (307 BC)

Today, more than $1 billion on average has to be invested to get one new drug to the market. However, many drugs are actually only effective and beneficial for a small part of the population. In addition, the timeframe and costs for clinical trials needed to register new chemical entities (NCEs) has been extended in many cases to sometimes over 10 years. The combination of decreasing R&D productivity and “imprecision medicine” represent a growing problem for health care which so far has been little-noticed.

We use our unique computational methods to discover and design active ingredients for difficult to drug disease targets.

Sanoosa’s advantage:

✓ 50-100x higher hit rates than HTS and only ca. 50 molecules necessary to test
✓ Only a minimum of experimental lab work needed
✓ Over 5x quicker
✓ Novel drug candidates 2 years earlier into human trials

We clarify druggability and mode of action at the earliest possible time and then follow through a structured and very disciplined process until we have a patentable compound. We achieve >2,000% productivity gains in target druggability evaluation.

Our MFMD technology is predestined to explore protein surfaces, protein-protein interactions and binding sites which are difficult to detect or to drug.

We are specialists in protein-protein / RNA- protein interaction inhibitors.

Sanoosa’s Compound Libraries & Non-trivial Chemistry

We have compiled a diverse virtual library of >250k compounds from a large >7 million compounds library that we use to discover novel scaffolds for our or our partners’ targets.

In addition, we have compiled a virtual library of 20,000 naturally occurring small active molecules. With our unique in-silico discovery platform we also screen this library against our drug targets of interest. Furthermore, we are complementing our libraries with carbon sp³-rich compounds. Restricted rotation and conformations of molecules allows for specific design for unconventional binding sites (incl. surfaces) and protein-protein interactions. This non-trivial chemistry and the related novel substitution patterns open up new chemical space/bioactivities.

Designing and synthesising amended naturally occurring compounds as well as sp³-rich compounds is part of Sanoosa’s capability portfolio.